AGP Executive Report
Last update: 10 hours agoHemp Legal Fight: A federal judge refused to pause Texas’s THC product ban, leaving the restrictions in place while the case moves forward. State-by-State Pressure: Virginia hemp businesses sued to block new THC limits that would end a key exception, arguing it could wipe out inventory and jobs. Congress Watch: A bipartisan bill would keep hemp THC drinks federally legal and regulated like alcohol, but the Senate also voted to delay the broader hemp THC ban again—showing how messy the rollout is. Clinical Cannabis: A placebo-controlled trial reports a standardized cannabis extract improved autism symptoms in kids and teens with mild, non-serious side effects. Safety Alarm: CDC-linked reporting shows ER diagnoses for cannabis hyperemesis syndrome (“scromiting”) jumped 16% from late 2025 to mid-2026, with more younger users. Medical R&D: Jazz Pharmaceuticals agreed to buy Actio Biosciences for ~$1.3B to expand epilepsy treatments, including a KCNT1 program.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
